ArticleJACC. Case reports2026
Axillary VA-ECMO Implantation Under Regional Block Anesthesia.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxillary venoarterial extracorporeal membrane oxygenation (VA-ECMO) implantation for refractory cardiogenic shock traditionally requires general anesthesia, risking hemodynamic compromise in critically ill patients. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: We report the first-in-human axillary VA-ECMO cannulation via Dacron tube graft performed under locoregional anesthesia with sedation in a 58-year-old man with SCAI stage D cardiogenic shock. The procedure was successfully completed, with excellent patient tolerance, hemodynamic stability, and preserved neurologic monitoring throughout. The patient achieved successful ECMO weaning after 7 days, with preserved limb function and no cannulation-related complications through 30-day follow-up. DISCUSSION: This novel approach avoided general anesthesia-related hemodynamic compromise while enabling continuous neurologic assessment. Subsequent patient mortality at 75 days resulted from unrelated device infections and was not attributable to the innovative cannulation technique. NOVELTY: This is the first reported axillary ECMO cannulation under regional anesthesia, eliminating general anesthesia risks in critically ill cardiac patients. TAKE-HOME MESSAGE: Regional anesthesia enables safe axillary ECMO cannulation in high-risk patients while preserving hemodynamic stability and neurologic monitoring capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.